Low levels of high-density lipoprotein (HDL) cholesterol correlate with an increased risk of atherosclerosis. Thus, pharmacological agents that increase HDL should be associated with reductions in cardiovascular disease and has been the focus of recent pharmaceutical research.
The primary anti-atherogenic effects of HDL occur through the reverse cholesterol transport (RCT) pathway. However, HDL also has anti-oxidative, anti-thrombotic, anti-inflammatory and endovascular properties.
HDL-raising through the cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib, was associated with increased cardiovascular morbidity and mortality, despite substantial increases of HDL levels (by ∼60%), leading to a suspension of all further research with this drug.
The strongest evidence for HDL-raising and beneficial cardiovascular outcomes is derived from trials with niacin. However, the use of niacin has been limited by its main side effect, skin flushing. The combination of extended-release niacin with a selective prostaglandin D2 receptor antagonist has been shown to decrease flushing, and clinical trials evaluating cardiovascular endpoints are underway.
Promising HDL-raising effects on cardiovascular outcomes have been shown using fibrates, statins, APOA1Milano, APOA1 mimetics and reconstituted HDL, although the actual beneficial mechanisms could be found to differ from theoretical mechanisms. Other potential therapies include liver X-receptor agonists, selective cannibinoid-1 receptor antagonists, pro-protein convertase activators and inhibitors of endothelial lipase, hepatic lipase or scavenger receptor-B1.
Despite the failure of torcetrapib, HDL-raising remains a potentially useful strategy for atheroprotection.
The dramatic failure of clinical trials evaluating the cholesterol ester transfer protein inhibitor torcetrapib has led to considerable doubt about the value of raising high-density lipoprotein cholesterol (HDL-C) as a treatment for cardiovascular disease. These results have underscored the intricacy of HDL metabolism, with functional quality perhaps being a more important consideration than the circulating quantity of HDL. As a result, HDL-based therapeutics that maintain or enhance HDL functionality warrant closer investigation. In this article, we review the complexity of HDL metabolism, discuss clinical-trial data for HDL-raising agents, including possible reasons for the failure of torcetrapib, and consider the potential for future HDL-based therapies.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
How radiation influences atherosclerotic plaque development: a biophysical approach in ApoE ¯/¯ mice
Radiation and Environmental Biophysics Open Access 02 September 2017
Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries
BMC Genomics Open Access 09 January 2009
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007). This randomized trial showed that among individuals at high risk of cardiovascular disease, treatment with torcetrapib (60 mg/day) plus atorvastatin (10–80 mg/day) versus atorvastatin alone was associated with an increased risk of cardiovascular events despite a 72% increase in HDL-C and 25% decrease in LDL-C levels.
Nissen, S. E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304–1316 (2007). This randomized trial showed that despite a 61% increase in HDL-C and a 20% decrease in LDL-C, torcetrapib in combination with atorvastatin versus atorvastatin alone did not significantly decrease the progression of coronary atherosclerosis among 1,188 patients with CHD.
Kastelein, J. J. et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356, 1620–1630 (2007). Compared to atorvastatin therapy alone, the combination of torcetrapib with atorvastatin did not further reduce carotid atherosclerosis but was associated with progression of atherosclerosis in the common carotid segment among 850 patients with heterozygous familial hypercholesterolaemia, despite a significant 50% elevation in HDL-C levels.
Bots, M. L. et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370, 153–160 (2007). Torcetrapib in combination with atorvastatin versus atorvastatin alone did not affect carotid atherosclerosis progression despite a 63% increase in HDL-C and 18% decrease in LDL-C.
Singh, I. M., Shishehbor, M. H. & Ansell, B. J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298, 786–798 (2007). An excellent systematic review outlining the clinical evidence of HDL-raising and atherosclerosis.
Kontush, A. & Chapman, M. J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol. Rev. 58, 342–374 (2006).
Rader, D. J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116, 3, 90–100 (2006). An excellent review describing the molecular aspects of HDL metabolism, including regulation, catabolism and function.
Schaefer, E. J. & Asztalos, B. F. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction? Curr. Opin. Cardiol. 22, 373–378 (2007).
Asztalos, B. F. et al. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J. Lipid Res. 46, 2246–2253 (2005).
Asztalos, B. F. et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20, 2670–2676 (2000).
Asztalos, B. F. et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 24, 2181–2187 (2004).
Asztalos, B. F. et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler. Thromb. Vasc. Biol. 25, 2185–2191 (2005).
Asztalos, B. F. et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler. Thromb. Vasc. Biol. 23, 847–852 (2003).
Pouliot, M. C. et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin and lipoprotein levels. Diabetes 41, 826–834 (1992).
Patsch, J. R., Karlin, J. B., Scott, L. W., Smith, L. C. & Gotto, A. M., Jr. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc. Natl Acad. Sci. USA 80, 1449–1453 (1983).
Ballantyne, F. C., Clark, R. S., Simpson, H. S. & Ballantyne, D. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism 31, 433–437 (1982).
Kontush, A., Chantepie, S. & Chapman, M. J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23, 1881–1888 (2003).
Sillanaukee, P., Koivula, T., Jokela, H., Myllyharju, H. & Seppa, K. Relationship of alcohol consumption to changes in HDL-subfractions. Eur. J. Clin. Invest. 23, 486–491 (1993).
Navab, M. et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88, 2039–2046 (1991).
Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C. & Witztum, J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320, 915–924 (1989).
Cockerill, G. W., Rye, K. A., Gamble, J. R., Vadas, M. A. & Barter, P. J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15, 1987–1994 (1995).
Nofer, J. R. et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113, 569–581 (2004).
Norata, G. D., Callegari, E., Inoue, H. & Catapano, A. L. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler. Thromb. Vasc. Biol. 24, 871–877 (2004).
Chen, L. Y. & Mehta, J. L. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci. 55, 1815–1821 (1994).
Saad, A. F., Virella, G., Chassereau, C., Boackle, R. J. & Lopes-Virella, M. F. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J. Lipid Res. 47, 1975–1983 (2006).
Ren, S. & Shen, G. X. Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20, 1688–1693 (2000).
Carson, S. D. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Lett. 132, 37–40 (1981).
Carson, S. D. Tissue factor (coagulation factor III) inhibition by apolipoprotein A-II. J. Biol. Chem. 262, 718–721 (1987).
Nofer, J. R. et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161, 1–16 (2002).
Griffin, J. H., Kojima, K., Banka, C. L., Curtiss, L. K. & Fernandez, J. A. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest. 103, 219–227 (1999).
Sviridov, D. & Nestel, P. J. Genetic factors affecting HDL levels, structure, metabolism and function. Curr. Opin. Lipidol. 18, 157–163 (2007).
Yoshikawa, M., Sakuma, N., Hibino, T., Sato, T. & Fujinami, T. HDL3 exerts more powerful antioxidative, protective effects against copper-catalysed LDL oxidation than HDL2. Clin. Biochem. 30, 221–225 (1997).
Marsche, G. et al. 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler. Thromb. Vasc. Biol. 24, 2302–2306 (2004).
Norata, G. D. et al. Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. Br. J. Haematol. 127, 97–104 (2004).
Mackness, B. et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107, 2775–2779 (2003).
Clofibrate and niacin in coronary heart disease. JAMA 231, 360–381 (1975).
Canner, P. L. et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245–1255 (1986).
Brown, G. et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323, 1289–1298 (1990).
Brown, B. G. et al. Simvastatin and niacin, antioxidant vitamins or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583–1592 (2001).
Frick, M. H. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237–1245 (1987).
Rubins, H. B. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410–418 (1999).
Zhang, Z. et al. Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis 159, 67–75 (2001).
Izem, L. & Morton, R. E. Possible role for intracellular cholesteryl ester transfer protein in adipocyte lipid metabolism and storage. J. Biol. Chem. 282, 21856–21865 (2007).
Tall, A. R. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34, 1255–1274 (1993).
Koizumi, J. et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 58, 175–186 (1985).
Inazu, A. et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323, 1234–1238 (1990).
Morehouse, L. A. et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J. Lipid Res. 48, 1263–1272 (2007).
Okamoto, H. et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406, 203–207 (2000).
Huang, Z., Inazu, A., Nohara, A., Higashikata, T. & Mabuchi, H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin. Sci. (Lond.) 103, 587–594 (2002).
de Grooth, G. J. et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105, 2159–2165 (2002).
Clark, R. W. et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24, 490–497 (2004).
Zhong, S. et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97, 2917–2923 (1996).
Bruce, C., Sharp, D. S. & Tall, A. R. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J. Lipid Res. 39, 1071–1078 (1998).
Agerholm-Larsen, B., Nordestgaard, B. G., Steffensen, R., Jensen, G. & Tybjaerg-Hansen, A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101, 1907–1912 (2000).
Borggreve, S. E. et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J. Clin. Endocrinol. Metab. 91, 382–388 (2006).
Gaofu, Q. et al. Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J. Cardiovasc. Pharmacol. 45, 591–598 (2005).
Sugano, M. et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273, 33–36 (1998).
Rittershaus, C. W. et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, 2106–2112 (2000).
Plump, A. S. et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19, 1105–1110 (1999).
Van Eck, M. et al. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ. Res. 100, 678–685 (2007).
Hayek, T. et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J. Clin. Invest. 96, 2071–2074 (1995).
Harder, C., Lau, P., Meng, A., Whitman, S. C. & McPherson, R. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice. Arterioscler. Thromb. Vasc. Biol. 27, 858–864 (2007).
Foger, B. et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 274, 912–920 (1999).
Lusis, A. J., Yu, J. & Wang, S. S. The problem of passenger genes in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 27, 2100–2103 (2007).
Sigmund, C. D. Viewpoint: are studies in genetically altered mice out of control? Arterioscler. Thromb. Vasc. Biol. 20, 1425–1429 (2000).
Davidson, M. H., McKenney, J. M., Shear, C. L. & Revkin, J. H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 48, 1774–1781 (2006).
McKenney, J. M., Davidson, M. H., Shear, C. L. & Revkin, J. H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. 48, 1782–1790 (2006).
Nissen, S. E. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071–1080 (2004).
Nissen, S. E. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295, 1556–1565 (2006).
Tall, A. R., Yvan-Charvet, L. & Wang, N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 27, 257–260 (2007).
Farrell, B., Godwin, J., Richards, S. & Warlow, C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatry 54, 1044–1054 (1991).
Lewington, S., Clarke, R., Qizilbash, N., Peto, R. & Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).
Ohta, T. et al. Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. J. Lipid Res. 36, 696–704 (1995).
Matsuura, F., Wang, N., Chen, W., Jiang, X. C. & Tall, A. R. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J. Clin. Invest. 116, 1435–1442 (2006).
Yvan-Charvet, L. et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 27, 1132–1138 (2007).
Brousseau, M. E. et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and faecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25, 1057–1064 (2005).
Clark, R. W., Ruggeri, R. B., Cunningham, D. & Bamberger, M. J. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. 47, 537–552 (2006).
Kuivenhoven, J. A. et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 95, 1085–1088 (2005).
Robins, S. J. et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285, 1585–1591 (2001).
Nissen, S. E. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292–2300 (2003).
Tardif, J. C. et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297, 1675–1682 (2007).
Taylor, A. J., Lee, H. J. & Sullenberger, L. E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin. 22, 2243–2250 (2006).
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K. & Grace, K. A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 512–517 (2004).
Blankenhorn, D. H. et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257, 233–240 (1987).
Kane, J. P. et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264, 7–12 (1990).
Malik, S. & Kashyap, M. L. Niacin, lipids and heart disease. Curr. Cardiol Rep. 5, 470–476 (2003).
Tunaru, S. et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nature Med. 9, 352–355 (2003).
Wise, A. et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278, 869–874 (2003).
Soga, T. et al. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. 303, 364–369 (2003).
Lai, E. et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 81, 849–857 (2007).
Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE [online], (1992).
Niacin plus statin to prevent vascular events [online], (2006).
Meyers, C. D., Kamanna, V. S. & Kashyap, M. L. Niacin therapy in atherosclerosis. Curr. Opin. Lipidol. 15, 659–665 (2004).
Hernandez, M., Wright, S. D. & Cai, T. Q. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem. Biophys. Res. Commun. 355, 1075–1080 (2007).
Sakai, T., Kamanna, V. S. & Kashyap, M. L. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler. Thromb. Vasc. Biol. 21, 1783–1789 (2001).
Morgan, J. M. et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am. J. Cardiol. 91, 1432–1436 (2003).
Chapman, M. J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171, 1–13 (2003).
Ericsson, C. G. et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347, 849–853 (1996).
No authors. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357, 905–910 (2001).
No authors. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102, 21–27 (2000).
Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9, 795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005).
Rodrigueza, W. V. et al. Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17, 2132–2139 (1997).
Newton, R. S. & Krause, B. R. HDL therapy for the acute treatment of atherosclerosis. Atheroscler. Suppl. 3, 31–38 (2002).
Navab, M., Hama, S., Hough, G. & Fogelman, A. M. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation 108, 1735–1739 (2003).
Rodrigueza, W. V., Klimuk, S. K., Pritchard, P. H. & Hope, M. J. Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim. Biophys. Acta 1368, 306–320 (1998).
Stamler, C. J. et al. Phosphatidylinositol promotes cholesterol transport in vivo. J. Lipid Res. 41, 1214–1221 (2000).
Burgess, J. W. et al. Phosphatidylinositol promotes cholesterol transport and excretion. J. Lipid Res. 44, 1355–1363 (2003).
Burgess, J. W. et al. Phosphatidylinositol increases HDL-C levels in humans. J. Lipid Res. 46, 350–355 (2005).
Nicholls, S. J. et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111, 1543–1550 (2005).
Lerch, P. G., Spycher, M. O. & Doran, J. E. Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb. Haemost. 80, 316–320 (1998).
Nicholls, S. J. et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. 25, 2416–2421 (2005).
Bisoendial, R. J. et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107, 2944–2948 (2003).
Spieker, L. E. et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105, 1399–1402 (2002).
Sumi, M. et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27, 813–818 (2007).
Garber, D. W. et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J. Lipid Res. 42, 545–552 (2001).
Navab, M. et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105, 290–292 (2002).
Ou, J. et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ. Res. 97, 1190–1197 (2005).
Ou, J. et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107, 2337–2341 (2003).
Li, X. et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110, 1701–1705 (2004).
Navab, M. et al. Potential clinical utility of high-density lipoprotein-mimetic peptides. Curr. Opin. Lipidol. 17, 440–444 (2006).
Franceschini, G., Sirtori, C. R., Capurso, A., 2nd, Weisgraber, K. H. & Mahley, R. W. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest. 66, 892–900 (1980).
Shah, P. K. et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97, 780–785 (1998).
Shah, P. K. et al. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 103, 47–50 (2001).
Weibel, G. L. et al. Wild-type apoA-I and the milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler. Thromb. Vasc. Biol. 27, 2022 (2007).
Lebherz, C., Sanmiguel, J., Wilson, J. M. & Rader, D. J. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc. Diabetol. 6, 15 (2007).
Favari, E. et al. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. J. Biol. Chem. 282, 125–132 (2007).
Berger, J. P., Akiyama, T. E. & Meinke, P. T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26, 244–251 (2005).
Buse, J. B. et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin. Ther. 27, 1181–1195 (2005).
Kendall, D. M. et al. Improvement of glycaemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29, 1016–1023 (2006).
Nissen, S. E., Wolski, K. & Topol, E. J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294, 2581–2586 (2005).
AstraZeneca discontinues development of GALIDATM (tesaglitzar) [online], (2006).
Jin, W. et al. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab. 6, 129–136 (2007).
Badellino, K. O., Wolfe, M. L., Reilly, M. P. & Rader, D. J. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med. 3, e22 (2006).
Rigotti, A. et al. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc. Natl Acad. Sci. USA 94, 12610–12615 (1997).
Brundert, M. et al. Scavenger receptor class B type I mediates the selective uptake of high-density lipoprotein-associated cholesteryl ester by the liver in mice. Arterioscler. Thromb. Vasc. Biol. 25, 143–148 (2005).
Trigatti, B. et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc. Natl Acad. Sci. USA 96, 322–327 (1999).
Braun, A. et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ. Res. 90, 270–276 (2002).
Beaven, S. W. & Tontonoz, P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 57, 313–329 (2006).
Grefhorst, A. et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 277, 182–190 (2002).
Brunham, L. R. et al. Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ. Res. 99, 672–674 (2006).
Miao, B. et al. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J. Lipid Res. 45, 1410–1417 (2004).
Bradley, M. N. et al. Ligand activation of LXRbeta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRalpha and apoE. J. Clin. Invest. 17, 2337–2346 (2007).
Despres, J. P., Golay, A. & Sjostrom, L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121–2134 (2005).
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J. & Rosenstock, J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295, 761–775 (2006).
Hollander, P. Endocannabinoid blockade for improving glycaemic control and lipids in patients with type 2 diabetes mellitus. Am. J. Med. 120, S18–28; discussion S29–32 (2007).
Suicide risk fears over diet pill [online], (15 June 2007).
Varady, K. A. & Jones, P. J. Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels? J. Nutr. 135, 1829–1835 (2005).
Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
Appel, L. J. et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 289, 2083–2093 (2003).
Ornish, D. et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280, 2001–2007 (1998).
Krause, B. R. & Princen, H. M. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis 140, 15–24 (1998).
Marotti, K. R. et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364, 73–75 (1993).
Berard, A. M. et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nature Med. 3, 744–749 (1997).
Hirano, K. et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinaemia caused by CETP gene mutation is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 17, 1053–1059 (1997).
Carlson, L. A. & Rosenhamer, G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223, 405–418 (1988).
Cashin-Haemphill, L. et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 264, 13–17 (1990).
Brown, B. G. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: A 10-year familial atherosclerosis treatment study (FATS) follow-up. Circulation 98, 635 (1998).
Frick, M. H. et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96, 2137–2143 (1997).
Dr. Hegele is supported by the Jacob J. Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics, a Career Investigator award from the Heart and Stroke Foundation of Ontario and operating grants from the Canadian Institutes for Health Research, the Heart and Stroke Foundation of Ontario, the Ontario Research Fund and Genome Canada through the Ontario Genomics Institute. Dr. Joy is supported by the Resident Research Fellowship Program through the Department of Medicine at the University of Western Ontario.
- High-density lipoprotein
(HDL). A class of cholesterol-rich lipoprotein particles that drive the return of cholesterol from the periphery back to the liver; cholesterol carried by these particles is colloquially referred to as 'good cholesterol'.
A complex, multifactorial disease process that results in the development of arterial wall plaques, which can eventually occlude the arterial lumen and compromise blood flow, resulting in a heart attack or stroke depending on the affected arterial bed. Plasma lipids — especially cholesterol — in circulating lipoprotein particles have a key role at several stages of atherosclerosis.
- Apolipoprotein A-1
(APOA1). The major structural apolipoprotein on the vast majority of high-density lipoprotein particles, accounting for approximately 70% of the protein content of these particles.
A member of the vitamin B family and effective cholesterol-lowering agent at high doses. It reduces low-density lipoprotein, triglyceride and total plasma cholesterol levels while raising high-density lipoprotein levels. It is the only known compound to effectively reduce the levels of lipoprotein A.
- Low-density lipoprotein
(LDL). A class of cholesterol-rich lipoprotein particles that deliver cholesterol from the liver to peripheral cells, including cells within the evolving atherosclerotic plaque; cholesterol carried by these particles is colloquially referred to as 'bad cholesterol'.
- Reverse cholesterol transport
(RCT). The general pathway through which cholesterol is transported from peripheral cells, such as cholesterol-laden macrophages, to the liver for excretion in bile. High-density lipoprotein (HDL) has a major role in RCT and this is thought to be the main mechanism by which HDL exerts its anti-atherogenic effects.
- Cholesteryl ester transfer protein
(CETP). A hydrophobic glycoprotein that is primarily found bound to high-density lipoproteins (HDL). The major function of CETP is to facilitate the transfer of cholesteryl ester from HDL to low-density lipoproteins, intermediate density lipoproteins and very low-density lipoproteins in exchange for triglyceride from those particles during the latter stages of reverse cholesterol transport.
The body's main mechanism of dissolving fibrin-formed clots and thus preventing adverse clot-initiated events such as heart attacks, deep vein thromboses or pulmonary emboli.
- Familial hypercholesterolaemia
(FH). A genetically inherited lipoprotein disorder characterized by cutaneous manifestations of hyper-cholesterolaemia, very high levels of low-density lipoprotein and total cholesterol, as well as early, often fatal, cardiovascular disease. FH is most often caused by defects in the low-density lipoprotein receptor (LDLR) gene.
- Heparin-affinity column
A chromatographic method that is used to separate and purify proteins based on their differential affinity to heparin.
- Tangier disease
A rare autosomal recessive lipoprotein disorder characterized by low to absent high-density cholesterol levels with deposition of cholesterol esters in reticuloendothelial cells, leading to tonsillar enlargement, hepatomegaly, splenomegaly and lymphadenopathy. The disease is caused by mutations in the ATP-binding cassette subfamily A, member 1 (ABCA1) gene.
- APOA1Milano mutation
A cysteine to arginine substitution at position 173 in the apolipoprotein A-1 (APOA1) gene. Individuals possessing this mutation have low levels of high-density lipoprotein cholesterol and increased levels of triglycerides without an associated increased risk for cardiovascular disease.
About this article
Cite this article
Joy, T., Hegele, R. Is raising HDL a futile strategy for atheroprotection?. Nat Rev Drug Discov 7, 143–155 (2008). https://doi.org/10.1038/nrd2489
This article is cited by
How radiation influences atherosclerotic plaque development: a biophysical approach in ApoE ¯/¯ mice
Radiation and Environmental Biophysics (2017)
Athero-protective Effects of High Density Lipoproteins (HDL): An ODE Model of the Early Stages of Atherosclerosis
Bulletin of Mathematical Biology (2014)
Nature Reviews Endocrinology (2013)
Nature Reviews Drug Discovery (2012)
Current Cardiovascular Risk Reports (2012)